Scholarlink

Background <p>Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and neuroinflammation, with microglial dysfunction playing a pivotal role in its pathogenesis. The specific function of the immune checkpoint molecule TIM-3 (encoded by HAVCR2) in microglia remains unclear.</p> Methods <p>We performed an integrated multi-omics analysis combining bulk and single-cell RNA sequencing datasets from AD patients. Bioinformatics approaches, including gene set enrichment, cell-cell communication, and pathway analysis. Furthermore, machine learning algorithms were used to stratify AD patients into molecular subtypes based on HAVCR2 expression. Finally, network pharmacology analysis was conducted to identify potential therapeutic compounds targeting TIM-3 + microglia.</p> Results <p>We identified a novel TIM-3 + microglial subset that drives pathogenesis through a dual mechanism: (i) sustained neuroinflammation via TNF-α/NF-κB and IL-6/JAK/STAT3 signaling, and (ii) impaired amyloid-β clearance linked to PI3K-AKT and FcγR pathways. TIM-3 + microglia displayed strong interactions with known AD risk genes such as INPP5D and TREM2. Clinically, machine learning classified AD patients into two molecular subtypes: a “hyper-inflammatory” subtype and a “metabolically dysregulated” subtype, revealing distinct pathological drivers. Network pharmacology predicted tretinoin (ATRA) as a candidate drug targeting the CD86–PTPRC–ITGAX axis in TIM-3 + microglia.</p> Conclusions <p>This study reveals the immunopathological role of TIM-3 + microglia in AD and highlights their contribution to neuroinflammation and impaired protein clearance. The identification of molecular subtypes and a potential drug candidate (ATRA) provides a framework for precision medicine strategies targeting microglial heterogeneity in Alzheimer’s disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-cell sequencing analysis and machine learning model reveal aberrant TIM-3 expression in microglia during Alzheimer’s disease progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月24日

查看全文
  • Zongtang Xu,
  • Minshan Chen,
  • Fengchu Liang,
  • Siyuan Song,
  • Jiawen Lei,
  • Xingting Huang,
  • Di Hu,
  • Ling Tang,
  • Pingyi Xu,
  • Lin Lu

摘要

Background

Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and neuroinflammation, with microglial dysfunction playing a pivotal role in its pathogenesis. The specific function of the immune checkpoint molecule TIM-3 (encoded by HAVCR2) in microglia remains unclear.

Methods

We performed an integrated multi-omics analysis combining bulk and single-cell RNA sequencing datasets from AD patients. Bioinformatics approaches, including gene set enrichment, cell-cell communication, and pathway analysis. Furthermore, machine learning algorithms were used to stratify AD patients into molecular subtypes based on HAVCR2 expression. Finally, network pharmacology analysis was conducted to identify potential therapeutic compounds targeting TIM-3 + microglia.

Results

We identified a novel TIM-3 + microglial subset that drives pathogenesis through a dual mechanism: (i) sustained neuroinflammation via TNF-α/NF-κB and IL-6/JAK/STAT3 signaling, and (ii) impaired amyloid-β clearance linked to PI3K-AKT and FcγR pathways. TIM-3 + microglia displayed strong interactions with known AD risk genes such as INPP5D and TREM2. Clinically, machine learning classified AD patients into two molecular subtypes: a “hyper-inflammatory” subtype and a “metabolically dysregulated” subtype, revealing distinct pathological drivers. Network pharmacology predicted tretinoin (ATRA) as a candidate drug targeting the CD86–PTPRC–ITGAX axis in TIM-3 + microglia.

Conclusions

This study reveals the immunopathological role of TIM-3 + microglia in AD and highlights their contribution to neuroinflammation and impaired protein clearance. The identification of molecular subtypes and a potential drug candidate (ATRA) provides a framework for precision medicine strategies targeting microglial heterogeneity in Alzheimer’s disease.